Furthermore, recent studies indicate that tumors deficient in SMARCB1, like synovial sarcoma and malignant rhabdoid tumors, exhibit a synthetic lethal dependency on BRD9 [82]. Here, SMARCB1 is linked to synovial sarcoma.